Articles tagged with Vaccine Development
A new study has discovered how antibodies help protect against Strep A infections and is contributing to the development of a Strep A vaccine. The research used the world's only human challenge model for Strep A, which uncovered the power and potential for this model to accelerate vaccine development.
A new TB vaccine candidate has shown complete protection and a superior immune response in nonhuman primates compared to the existing BCG vaccine. The delta sigH vaccine resulted in a more balanced and effective elimination of the bacteria, with lower levels of inflammation and a different type of interferon triggered.
Researchers have identified powerful antibodies capable of neutralizing a wide range of norovirus strains, paving the way for designing a broadly effective norovirus vaccine. The discovery brings us closer to a vaccine that could provide lasting protection and prevent devastating effects of norovirus outbreaks.
A risk prediction model was developed to identify patients unlikely to complete HPV vaccination. The model uses patient demographics and clinical characteristics to guide targeted interventions, increasing vaccination rates among high-risk groups.
Richard Willson, a University of Houston professor, has been elected Fellow of the Royal Society of Chemistry for his contributions to the chemical sciences. He has developed innovative methods to detect viruses and other biological threats using glow-in-the-dark nanoparticles.
Researchers developed a new vaccine platform that provides robust, long-lasting protection against multiple flu strains and COVID-19. The vaccine boasts 100% survival rates in vaccinated mice following challenge with either virus.
Lyme disease is a bacterial infection transmitted by ticks, posing an increasing threat in the U.S. Montana State University's Patrick Secor will study adaptations in Borrelia burgdorferi to illuminate how it circumvents its host's immune system. The goal is to discover new vaccine antigens and develop more effective treatments.
Researchers analyzed protein-coding RNA transcripts from single cells and lung fluid of infected pigs, monitoring immune cell alterations triggered by PRRSV strains of varying virulence. They found that high-virulence PRRSV caused severe lung damage and immune imbalance, while less virulent strains led to delayed lung damage with fewer...
A groundbreaking study published in eBioMedicine has shown that a new mRNA vaccine is effective in boosting immunity against tuberculosis. The vaccine demonstrated potent immune responses in infected mice and improved long-term protection when combined with the BCG vaccine.
A US clinical trial will assess the safety and efficacy of a nasal COVID-19 vaccine developed using technology from Washington University in St. Louis. The trial, sponsored by the National Institute of Allergy and Infectious Diseases, aims to evaluate the vaccine's ability to induce strong immunity in the nose and upper respiratory tract.
A new biodegradable polymer-based delivery system efficiently transports mRNA, outperforming existing lipid nanoparticles in delivery efficiency and expression duration. The study also shows improved immune response results without liver accumulation or toxicity.
A broadly neutralizing antibody has been shown to protect monkeys against severe H5N1 avian flu disease. The antibody's stable structure ensures it can withstand virus variants, providing universal protection against a globally spreading airborne infection. Serum levels of the antibody remained stable for up to 12 weeks.
Researchers developed a new approach to quickly identify mutations that enable viral immune escape. By analyzing the effects of individual mutations in reverse, they found three key mutations in the spike protein responsible for immune evasion.
Scientists at Tel Aviv University successfully transport mRNA-based drugs to the immune system of small and large intestines without passing through the liver. The breakthrough could enable treatments for inflammatory diseases such as Crohn's and colitis.
Researchers develop BEND lipids to improve LNP mRNA delivery and gene editing by breaking through the endosomal membrane. The new lipids outperform existing LNPs used in COVID-19 vaccines, with improved efficacy rates up to tenfold.
Researchers at the University of Queensland have identified a new henipavirus, Camp Hill virus, in shrews in Alabama, USA. The discovery suggests these viruses may be more globally distributed than previously thought, with implications for human health and vaccine development.
The foundation has awarded eight recipients of the 2025 Damon Runyon-Rachleff Innovation Award, including five early-career researchers with initial grants of $400,000 over two years. The awardees aim to develop novel cancer therapies using innovative approaches such as engineered skin bacteria and small molecule-boosted drug delivery.
Researchers developed MUNIS, a deep learning tool that predicts CD8+ T cell epitopes with high accuracy, potentially accelerating vaccine development. The tool was validated using experimental data from influenza, HIV, and EBV, demonstrating its potential to streamline vaccine design.
Southwest Research Institute's Risk Evaluation & Medical Decision Efficacy (REMEDY) tool supports agile medical decisions on countermeasures for chemical and biological threats. The REMEDY mission risk evaluations quantify risks and benefits of medical countermeasures, enabling operational planners to make informed decisions.
Researchers at Terasaki Institute develop lipopeptide hydrogels to deliver peptide-based cancer vaccines, demonstrating sustained release and enhanced immune cell uptake. The system shows promise in overcoming limitations of traditional peptide-based vaccines.
A West Virginia University legal scholar argues that current laws favor biologic drugs with longer exclusivity periods, affecting their pricing. The scholar suggests reducing exclusivity for biologics to bring them in line with small-molecule drugs, which could lower drug costs.
Cancer vaccines hold transformative potential, leveraging neoantigens to activate the immune system against tumors. UK researchers are positioning themselves for a strategic shift in cancer vaccine trials, recognizing opportunities for improvement.
A novel diagnostic system called TwinDemic Detection offers simultaneous and rapid detection of SARS-CoV-2 and influenza A virus. The system has a detection limit of 0.46 picomolar for CoV and 0.39 pM for IAV, correctly predicting positive and negative samples in high percentages.
Researchers at the University of São Paulo's Medical School have developed a COVID-19 vaccine using virus-like particles (VLPs), which proved highly protective, safe, and versatile in animal trials. The vaccine can be easily updated to combat variants of concern without requiring an adjuvant.
A new self-destructing vaccine provides improved safety and protection against TB in macaque monkeys, outperforming the standard BCG vaccine. The 'kill switch' mechanism eliminates the risk of accidental infection, offering a safer vaccination option for immunocompromised individuals.
Scientists discovered that T cells can prevent acute viral infections, challenging traditional views on sterilising immunity and herd immunity. The study found that T cells controlled viral loads and antibodies produced, and were effective in preventing infection to undetectable levels in some participants.
Researchers at the University of Gothenburg have discovered an antibody-like molecule, E10, that can protect mice from various influenza viruses. The molecule targets a conserved part of the virus's surface protein shared across multiple influenza types, providing effective protection against seasonal epidemics.
Researchers at NIH have identified a novel class of anti-malaria antibodies that target previously untargeted regions of the parasite. These antibodies have shown promise in providing protection against malaria parasites in animal models and could lead to new prevention methods.
Researchers developed AI-driven therapeutic platform mimicking viral structures to deliver therapeutic genes to target cells. The innovative approach achieved precise symmetrical structures and effectively delivered payloads, paving the way for breakthroughs in gene therapies and next-generation vaccines.
Researchers provide comprehensive review of RSV's virology, clinical impact, and prevention strategies, emphasizing the need for effective vaccines to mitigate this critical health need. The review highlights RSV's severe impact on infants, children, and older adults, as well as its potential effects on multiple organs and systems.
A live-attenuated vaccine against Lassa virus has been developed and shown to be safe and 100% effective in protecting guinea pigs from the virus. The vaccine was created by modifying the genome of the virus to prevent it from causing disease, making it a promising candidate for future clinical trials.
EBViously aims to prevent infectious mononucleosis and secondary diseases such as ME/CFS, while also protecting against certain types of cancer. The company's innovative vaccine candidate uses virus-like particles derived from EBV to trigger a targeted immune response.
Researchers created an advanced computational model to optimize maternal vaccine design and protect high-risk populations. The model helps reveal which antibodies can pass through effectively and when, enabling the development of safer, more effective vaccines.
Researchers at Washington University in St. Louis are developing vaccines to target misfolded proteins in the brain, with a focus on preventing inflammation and using peptide nanofibers. The goal is to prevent dementia by training the immune system against amyloid beta and tau proteins.
Researchers found that antibodies targeting a specific site on the malaria parasite's virulence protein bind to the human host's endothelial protein C receptor, neutralizing the parasite. The discovery provides new insights into prevention and treatment of severe malaria.
The American Heart Association has released its list of top cardiovascular research for 2024, focusing on prevention, treatment and the benefits of anti-obesity medications. The research highlights improvements in assessing cardiovascular risk, identifying early prevention opportunities and treating heart failure.
Researchers found a powerful antioxidant in Deinococcus radiodurans that combines with manganese to protect against radiation damage. The discovery could lead to synthetic antioxidants tailored for human needs, protecting astronauts and preparing for radiation emergencies.
Scientists at The Jackson Laboratory have identified the CAST/EiJ mouse as a highly susceptible model for studying severe COVID-19. This genetically pure background allows researchers to investigate the virus's impact without artificial receptor modifications, mirroring human responses. Initial trials using antiviral treatments show pr...
A novel vaccine design has demonstrated robust immune response and broad neutralization of HCV strains in mouse models. The innovative approach employs epitope-focused immunogens, which could pave the way for an effective HCV vaccine, potentially limiting its global spread.
A team of UCalgary researchers, led by Dr. Anthony Schryvers, has developed a new vaccine to protect cattle from hemorrhagic septicemia, a deadly bacterial disease that destroys livestock and livelihoods. The vaccine is designed with a long-lasting immune response and has been patented.
Researchers have discovered a monoclonal antibody capable of targeting multiple SARS-CoV-2 variants, including recent Omicron strains. K4-66's exceptional ability to adapt to the virus's frequent mutations makes it a promising candidate for vaccine and therapy development.
Researchers at Penn School of Engineering and Applied Science have developed a new method to refine ionizable lipids, key ingredients in lipid nanoparticles. This approach combines precision with rapid output, enabling safer and more effective mRNA vaccines and therapeutics.
Researchers are developing a novel vaccine and exploring the use of bile acids to fight necrotic enteritis, a preventable intestinal disease in poultry that costs the industry up to $6 billion annually. The vaccine, known as MEFA, targets multiple virulence points of the disease-causing pathogen, providing better protection against inf...
Researchers developed an ingestible capsule that releases a burst of drugs into the stomach or other organs, eliminating the need for injections. The capsule uses compressed carbon dioxide or tightly coiled springs to propel liquid drugs out, targeting specific parts of the digestive tract.
Researchers at Scripps Research have analyzed the molecular structure of viral proteins and developed a more stable form to create effective vaccines. The new design may lead to combination vaccines that target both RSV and human metapneumovirus, reducing hospitalizations for vulnerable populations.
Researchers developed a nasal vaccine combining traditional pertussis antigens with an innovative adjuvant called T-vant to boost immune response. The new vaccine was shown to prevent the bacteria's colonization in the respiratory tract, significantly curbing whooping cough spread.
Scientists have developed an experimental vaccine that combines the benefits of both vaccine strategies, using a horsepox virus to confer safety in a single shot. The new vaccine is substantially more attenuated than the vaccinia virus used in existing vaccines, reducing the risk of side effects and triggering systemic infections.
Researchers created tiny lab-grown models of human immune systems to study immune function in cancer and predict disease treatment response. The miniature models support longer cell function, allowing processes like antibody formation to occur similar to the human body.
Researchers at Cleveland Clinic have made significant progress in their novel vaccine aimed at preventing triple-negative breast cancer. The study found that the investigational vaccine was generally well-tolerated and produced an immune response in most patients, with the highest tolerated dose to date identified.
Researchers at Kumamoto University have developed a cutting-edge diagnostic tool, Intelli-OVI, to rapidly identify emerging SARS-CoV-2 variants. This system combines advanced DNA detection technology with computational algorithms to offer a quicker and more cost-effective method of monitoring viral mutations.
Researchers at Argonne National Laboratory have developed an AI-driven protein design framework that uses multimodal data to speed up the design of new proteins. The framework has been selected as a finalist for the prestigious Gordon Bell Prize, recognizing breakthroughs in high-performance computing.
The TEDDY study aims to understand the causes of type 1 diabetes in children, finding a connection between enterovirus infection, autoantibodies, and disease development. Probiotics may also reduce risk in infants at high danger of developing diabetes-related antibodies.
A phase Ib clinical trial has shown that the MVA-MERS-S vaccine candidate is safe and effective in healthy individuals previously infected with SARS-CoV-2. The vaccine was tested in a placebo-controlled study with no serious vaccine-related side effects, indicating promising results.
Researchers at Nagoya University developed an innovative synthesis technology to produce high-purity, fully chemically synthesized mRNA. This breakthrough cuts down the production time and can be used to address concerns about purity and speed in mRNA vaccine development.
Induced resistance, a plant-based approach, prepares plants to fight pests and disease by activating their immune systems. This holistic strategy combines multiple methods for tailored protection, enhancing abilities beyond just one defense mechanism.
A study by Johns Hopkins Medicine found distinct immune 'signatures' in patients who developed adverse events while taking immunotherapy. These signatures, including increases in white blood cells known as Th2 and Th17, predict the development of immune-related adverse events and may be targeted for treatment.
A new report argues that countries can cut premature mortality in half by 2050 through targeted health investments. By prioritizing the 15 health conditions causing most premature deaths and implementing public subsidies for essential medicines and diagnostics, nations can achieve this goal.
Scientists at St. Jude Children's Research Hospital found that nutrient availability affects T cell development and mitochondrial activity, inhibiting T cell formation in lysosomes. The study highlights the crucial role of organelle signaling, such as mitochondrial and lysosomal function, in shaping tissue immunity.
The authors emphasize the importance of increasing vaccination rates to combat decreasing rates globally. They also highlight emerging challenges such as a highly virulent strain of influenza and measles outbreaks, particularly in areas with low vaccination rates.
Researchers at Houston Methodist are working on a national consortium to develop vaccines against two common and destructive strains of herpesviruses. The project aims to create prophylactic and therapeutic vaccines using a computational toolkit that could transform vaccine development.